As part of the implementation of the national project “Fight against oncological diseases”, modern anti-tumor drugs of targeted action are being actively introduced into the healthcare system of the Russian Federation. The use of FMS-like tyrosine kinase 3 (FLT3) inhibitors in programmatic polychemotherapy of acute myeloid leukemias, based on genetic stratification, proved effective despite the epidemic risks caused by the pandemic of the COVID-19. In the context of the structural restructuring of healthcare due to the global infectious threat, the research data is discussed from the point of view of the transition to personalized medical services, which are provided at the expense of compulsory medical insurance.
A. V. Vinogradov (Wed,) studied this question.